Treatment of severe hospital-acquired and ventilator-associated pneumonia: A systematic review of inclusion and judgment criteria used in randomized controlled trials

Critical Care

Volumn 21, Issue 1, 2017, Pages

  Weiss, Emmanuel ^a,b,c   Essaied, Wafa ^d   Adrie, Christophe ^e   Zahar, Jean Ralph ^d,f   Timsit, Jean François ^b,d  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^d UNIVERSITÉ PARIS DIDEROT   (France)

^e Hôpital Avicenne ^*  (France)

^f AVICENNE HOSPITAL   (France)

Author keywords

Endpoints; Hospital acquired pneumonia treatment; Inclusion criteria; Randomized controlled trials; Systematic review; Ventilator acquired pneumonia treatment

Indexed keywords

AMIKACIN; AVIBACTAM PLUS CEFTAZIDIME; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; CEFTOLOZANE PLUS TAZOBACTAM; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; COLISTIMETHATE; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DORIPENEM; FOSFOMYCIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MEROPENEM PLUS VABORBACTAM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; PLAZOMICIN; RELEBACTAM; RIFAMPICIN; SULTAMICILLIN; TEDIZOLID; TELAVANCIN; TIGECYCLINE; TOBRAMYCIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

APACHE; ARTICLE; ARTIFICIAL VENTILATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; HOSPITAL ACQUIRED PNEUMONIA; HUMAN; INTENSIVE CARE; LENGTH OF STAY; LOW DRUG DOSE; MORTALITY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; VENTILATOR ASSOCIATED PNEUMONIA; CROSS INFECTION; INTENSIVE CARE UNIT; ORGANIZATION AND MANAGEMENT; PROCEDURES; STANDARDS;

ANTI-BACTERIAL AGENTS; CROSS INFECTION; HUMANS; INTENSIVE CARE UNITS; PNEUMONIA, VENTILATOR-ASSOCIATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATION, ARTIFICIAL;

EID: 85021257061     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/s13054-017-1755-5     Document Type: Article

References (16)

1. Nathan C, Cars O. Antibiotic resistance-problems, progress, and prospects. N Engl J Med. 2014;371(19):1761-3.
2. Guidance for Industry Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Developing Drugs for Treatment. In: U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER); 2014.
3. Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. In: European Medical Agency; 2013.
4. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med. 1999;27(5):887-92.
5. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, Napolitano LM, O'Grady NP, Bartlett JG, Carratala J, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61-e111.
6. Bartlett JG, Barie PS, Niederman MS, Wunderink RG. Workshop on clinical trials of antibacterial agents for hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S1-3.
7. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:g7647.
8. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic "blind" bronchoalveolar lavage fluid. Am Rev Respir Dis. 1991;143(5 Pt 1):1121-9.
9. Powers JH. Recommendations for improving the design, conduct, and analysis of clinical trials in hospital-acquired pneumonia and ventilator-associated pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S18-28.
10. Klompas M. Does this patient have ventilator-associated pneumonia? JAMA. 2007;297(14):1583-93.
11. Heyland DK, Dodek P, Muscedere J, Day A, Cook D, Canadian Critical Care Trials G. Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med. 2008;36(3):737-44.
12. Kollef MH. Review of recent clinical trials of hospital-acquired pneumonia and ventilator-associated pneumonia: a perspective from academia. Clin Infect Dis. 2010;51 Suppl 1:S29-35.
13. Timsit JF, de Kraker MEA, Sommer H, Weiss E, Bettiol E, Wolkewitz M, Nikolakopoulos S, Wilson D, Harbarth S, consortium C-N. Appropriate endpoints for evaluation of new antibiotic therapies for severe infections: a perspective from COMBACTE's STAT-Net. Intensive Care Med. 2017. doi: 10.1007/s00134-017-4802-4. Epub ahead of print.
14. Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, Society of Critical Care Medicine, Spellberg B, Talbot G. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51 Suppl 1:S150-170.
15. Sorbello AK, Komo S, Valappil T. Noninferiority margin for clinical trials of antibacterial drugs for nosocomial pneumonia. Drug Inf J. 2010;44:165-76.
16. Evans SR, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler Jr VG, et al. Desirability of outcome ranking (DOOR) and response adjusted for duration of antibiotic risk (RADAR). Clin Infect Dis. 2015;61(5):800-6.